Metastatic 0 10 0 10 B-cancer
or 11 13 11 13 I-cancer
inoperable 14 24 14 24 I-cancer
urothelial 25 35 25 35 I-cancer
cancer 36 42 36 42 I-cancer

No 0 2 43 45 O
prior 3 8 46 51 B-treatment
systemic 9 17 52 60 I-treatment
chemotherapy 18 30 61 73 I-treatment
treatment 31 40 74 83 I-treatment
in 41 43 84 86 O
the 44 47 87 90 O
metastatic 48 58 91 101 B-cancer
setting 59 66 102 109 O

Patients 0 8 110 118 O
with 9 13 119 123 O
disease 14 21 124 131 O
that 22 26 132 136 O
is 27 29 137 139 O
suitable 30 38 140 148 O
for 39 42 149 152 O
local 43 48 153 158 B-treatment
therapy 49 56 159 166 I-treatment
administered 57 69 167 179 O

Prior 0 5 180 185 B-treatment
treatment 6 15 186 195 I-treatment
with 16 20 196 200 O
an 21 23 201 203 O
anti 24 28 204 208 B-treatment
- 28 29 208 209 I-treatment
PD1 29 32 209 212 I-treatment
, 32 33 212 213 O
anti 34 38 214 218 B-treatment
- 38 39 218 219 I-treatment
PDL1 39 43 219 223 I-treatment
, 43 44 223 224 O
anti 45 49 225 229 B-treatment
- 49 50 229 230 I-treatment
PDL2 50 54 230 234 I-treatment
, 54 55 234 235 O
anti 56 60 236 240 B-treatment
- 60 61 240 241 I-treatment
CD137 61 66 241 246 I-treatment
, 66 67 246 247 O
or 68 70 248 250 O
anti 71 75 251 255 B-treatment
- 75 76 255 256 I-treatment
CTLA4 76 81 256 261 I-treatment
antibody 82 90 262 270 I-treatment
, 90 91 270 271 O
or 92 94 272 274 O
any 95 98 275 278 O
other 99 104 279 284 O
antibody 105 113 285 293 O
or 114 116 294 296 O
drug 117 121 297 301 O
specifically 122 134 302 314 O
targeting 135 144 315 324 O
T 145 146 325 326 B-treatment
- 146 147 326 327 I-treatment
cell 147 151 327 331 I-treatment
co 152 154 332 334 I-treatment
- 154 155 334 335 I-treatment
stimulation 155 166 335 346 I-treatment
or 167 169 347 349 O
checkpoint 170 180 350 360 B-treatment
pathways 181 189 361 369 I-treatment

have 0 4 370 374 O
at 5 7 375 377 O
least 8 13 378 383 O
1 14 15 384 385 B-lower_bound
lesion 16 22 386 392 O
with 23 27 393 397 O
measurable 28 38 398 408 O
disease 39 46 409 416 O

